BNTX
BioNTech SE
97.60$
+0.8%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
BioNTech SE (BNTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at 11 million EUR. Tick rows to compare them in a chart.
All figures in millions of EUR.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -35 | -35 | 14 | -2.8 | -31 | -54 | -49 | -64 | -55 | -16 | -193 | 249 | -311 | -100 | 1,501 | -200 | 4,050 | 3,919 | 4,779 | 829 | -677 | 4,387 | 811 | 851 | -344 | 1,759 | -688 | -501 | -822 | 132 | 855 | 299 | -428 | 11 | 737 | |
| 4.4 | 4.4 | 5.0 | 8.2 | 7.2 | 8.4 | 8.5 | 9.8 | 8.6 | 8.8 | 8.8 | 13 | 13 | 16 | 20 | 26 | 28 | 33 | 34 | 29 | 31 | 32 | 41 | 85 | 42 | 54 | 49 | 176 | 45 | 58 | 145 | 163 | 123 | 271 | 702 | |
| – | – | – | 7.6 | 13 | 4.5 | 4.5 | 7.8 | 8.4 | 8.3 | 8.1 | 8.0 | 17 | 22 | 23 | 18 | 11 | 15 | 61 | 27 | 8.6 | 13 | 16 | 14 | 16 | 20 | 41 | 24 | 22 | 32 | 28 | 24 | 23 | 21 | 96 | |
| – | 0.0 | 3.4 | 8.7 | 13 | 4.2 | 4.2 | 7.9 | 7.7 | 6.0 | 9.5 | 2.6 | 475 | 1,340 | 1,369 | -1,932 | -173 | -389 | 76 | -30 | -30 | -30 | -30 | – | – | – | – | – | – | – | – | – | – | – | – | |
| -6.1 | -6.1 | 30 | -18 | -11 | -17 | -32 | -23 | -18 | 58 | -1.0 | -133 | -1,928 | -4,244 | -3,099 | -1,460 | 497 | 2,603 | 2,884 | -1,466 | 48 | 4,705 | 639 | -1,775 | 241 | 2,554 | -723 | -745 | -438 | 570 | 730 | -215 | 67 | 607 | 1,189 | |
| 6.2 | 6.2 | 6.7 | 21 | 34 | 6.6 | 21 | 9.5 | 8.4 | 17 | 20 | 40 | 29 | 30 | 41 | 53 | 61 | 75 | 83 | 145 | 55 | 309 | 151 | 292 | 149 | 152 | 91 | 100 | 651 | 568 | 43 | 62 | 58 | 56 | 218 | |
| -20 | -20 | -6.6 | -21 | -33 | -13 | -21 | -10 | -15 | -9.8 | -20 | -100 | -28 | -30 | -408 | -467 | 287 | -78 | -83 | -161 | -735 | -2,292 | -1,232 | -2,835 | -2,501 | -249 | -163 | 649 | 1,312 | -27 | -996 | -2,627 | 2,694 | -104 | -1,032 | |
| – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | 484 | 484 | 484 | 484 | 15 | 9.8 | – | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | |
| – | 229 | 0.0 | 362 | 0.0 | 0.2 | 0.0 | 0.0 | – | 148 | 680 | – | – | – | – | – | – | -287 | -644 | -56 | -282 | -154 | -302 | 9.4 | 0.0 | 0.0 | 0.0 | 0.0 | – | 0.0 | – | – | – | -132 | – | |
| – | 0.0 | 2.3 | 3.4 | 1.0 | 1.1 | 1.1 | 2.1 | 2.0 | -1.6 | 98 | 43 | -4.5 | -8.0 | -5.3 | -49 | -30 | -10 | -9.6 | -9.3 | -9.3 | -9.3 | -9.3 | – | – | – | -7.9 | -7.3 | -14 | -13 | -12 | -12 | 26 | 21 | 23 | |
| 114 | 114 | 55 | 83 | 1.0 | 4.0 | 249 | 130 | 2.0 | 146 | 630 | 116 | -4.5 | 153 | -5.3 | -49 | 80 | -782 | -653 | -65 | -291 | -163 | -311 | -3.2 | -8.5 | -25 | -8.7 | -8.1 | -15 | -15 | -14 | -14 | 27 | -111 | -112 | |
| 61 | 61 | 60 | 58 | -63 | -63 | 178 | 56 | -68 | 121 | 418 | 220 | -319 | 23 | 1,112 | -700 | 4,471 | 3,171 | 4,089 | 451 | -1,731 | 2,023 | -671 | -1,404 | -3,190 | 1,427 | -380 | -633 | 893 | 1,053 | -196 | -2,421 | 2,118 | -276 | -775 | |
| -41 | -41 | 7.5 | -24 | -65 | -61 | -71 | -73 | -63 | -33 | -213 | 210 | -341 | -130 | 1,460 | -253 | 3,989 | 3,844 | 4,696 | 685 | -732 | 4,077 | 660 | 1,143 | -493 | 1,607 | -779 | -602 | -1,472 | 700 | 811 | 238 | -486 | -45 | 518 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.